Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2025-11-19 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Certification of Interim Filings' (Form 52-109FV2) signed by the CFO. This is a regulatory requirement for Canadian venture issuers to certify the accuracy of their interim financial reports and MD&A. Since it is a standalone regulatory certification document rather than the financial report itself or an announcement of one, it falls under the 'Regulatory Filings' category.
2025-11-19 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory certification form for venture issuers. It serves as an officer attestation regarding the review and accuracy of interim filings. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even when referencing interim reports, should be classified as Regulatory Filings (RNS) rather than the report itself, as it contains no actual financial statements or substantive financial data. 9M 2025
2025-11-19 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management's Discussion and Analysis' (MD&A) for LSL Pharma Group Inc. for the third quarter ended September 30, 2025. It provides a detailed narrative explanation of the company's financial condition, operating results, business segments, corporate strategy, and M&A activities. It is not a standalone financial statement or an earnings release, but rather the management commentary that accompanies financial reporting. Therefore, it fits the definition of an MDA filing.
2025-11-19 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of 'Condensed Interim Consolidated Financial Statements' for LSL Pharma Group Inc. for the three and nine-month periods ended September 30, 2025. It includes the Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Equity, Statement of Cash Flow, and detailed explanatory notes. It is not an announcement or a summary, but the actual financial report for an interim period, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-11-19 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing the completion of an acquisition (Laboratoire Du-Var Inc.) by LSL Pharma Group. It details the strategic rationale, financial considerations, and impact of the transaction. This falls under the category of M&A activity (Mergers and Acquisitions).
2025-11-18 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing Health Canada’s approval for six new sterile ophthalmic solutions. It contains no financial results, no shareholder meeting details, no regulatory statutory report, no capital or share issuance, no governance or legal update, and no earnings or annual/interim financial report. It is a general regulatory announcement about a product approval and therefore does not fit any specific category except the fallback “Regulatory Filings (RNS).”
2025-10-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.